scioDiscover - Protein Profiling on the Expression Level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised range of protein profiling services available. These help you to speed up your research and generate important data at lower cost through a highly-parallel protein expression level analysis using our Scio-Discover Antibody Microarray Platform. Furthermore, you may link to and verify your Genomics and Transcriptomics data with protein expression levels.

 

Applications:Experimental design of an antibody microarray profiling study

  • Pre-clinical Toxicology Studies
    • rodents such as mice* and rats*
    • cell culture models
    • tissue culture models
  • Drug target identification and verification
  • Mechanistic studies for various indications
  • Profile cytokine and inflammatory status
  • Protein Biomarker identification and verification

 

Key advantages:

  • High multiplexity (more than 1,400 proteins in parallel)
  • Low sample consumption
  • Investigation of human and murine samples*
  • Fast turnaround time, as low as two weeks**
  • No need for laborious depletion or fractionation of your samples
  • High sensitivity (as sensitive as an ELISA or better)
  • High reproducibility (CV < 10%)
  • Various sample types can be investigated
    • Plasma or Serum
    • fresh-frozen tissue samples
    • Cell culture samples
    • Cerebrospinal fluid (CSF)

 

Overview
Scio-Discover
    Biomarker
Discovery
    Contact
us

 

Reference Customers:

  • Dr. Ghaith Bakdash, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands
  • Dr. Anke Dienelt, Julius Wolff Institut, Charité, Berlin, Germany
  • Dr. Eric Eldering, Academic Medical Center, Amsterdam, The Netherlands
  • Dr. Reece Marillier, Ludwig Institute for Cancer Research Ltd, Brussels, Belgium
  • Prof. Jose L. Peiró, Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, USA
   

 

* Antibody array is designed to target human proteins. Due to a high sequence homology of vast majority of proteins it was often successfully applied to study murine, rat and ovine models as well  [Thorenz A. et al. (2018), Peiro J. et al. (2018), Reichman H. et al. (2019), Raquel F. et al. (2020)].

** Depending on study design and sample numbers.

 

Publications using scioDiscover

Article | Exploration of Novel Biomarkers for Neurodegenerative Diseases

| December 2024 | Biomarker candidates for neurodegenerative diseases were identified by combining an exploratory proteomic approach with quantitative ligand-binding assays. Sciomics supported this study by proteomic screening of plasma and CSF samples of patients with different neurodegenerative diseases using the scioDiscover microarray platform.

Kenzelmann A, et al.. Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays. Biomedicines. 2024;12(12):2794.  

Article | Vago-splenic signal transduction of cardioprotection in humans

| April 2024 | The spleen as a relay organ as well as the vagal innervation determine cardioprotective signal transduction of Remote Ischaemic Conditioning (RIC) and Auricular Tragus Stimulation (ATS). Sciomics contributed to this study by analysing plasma-dialysate samples using the scioDiscover microarray platform.

Lieder HR, Paket U, Skyschally A, et al. Vago-splenic signal transduction of cardioprotection in humans. Eur Heart J. 2024;45(34):3164-3177. 

Article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19  disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)

Article | Microbiota influences chemotherapy in pancreatic cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)

Article | Cycle-dependent biomarkers in endometriosis

| May 2022 | In a study by Maja Pušić et al. Cycle-dependent plasma protein biomarkers for peritoneal endometriosis were identified by our scioDiscover platform.

Pušić, M. et al. Antibody Arrays Identified Cycle-Dependent Plasma Biomarker Candidates of Peritoneal Endometriosis. J. Pers. Med. 202212, 852.

Testimonials scioDiscover protein profiling

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

Kyriaki Barmpa

PhD Candidate, Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine, University of Luxembourg

"By collaborating with Sciomics, we conducted a detailed analysis of the proteome of striatum organoids, uncovering significant differences that further assisted our research. Their communication was highly efficient, and the results were delivered promptly."

Product: scioPhospho

Our protein profiling services

scioDiscover - In depth profiling on the protein level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…

scioUbi: protein profiling and ubiquitination status

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse more than 1,400 proteins in a single assay.   Features Screen…

scioPhospho: phosphoproteomics and protein profiling service

Discover protein abundance and phosphorylation analysis in one step by our high-throughput scioPhospho platform. Simultaneous detection of protein levels & phosphorylation status of > 1,500 proteins. Our scioPhospho protein phosphorylation…

scioCD - Cell Surface Marker and Cytokine Profiling

Immune response profiling Cellular composition and signalling CD-Marker Expression Profiles       Our scioCD profiling service covers 349 different proteins : up to 141 unique CD-marker molecules up to 119 cytokines and chemokines

scioCyto : Cytokine Profiling

scioCyto is a high-content analysis service for a multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or cell culture supernatants can be screened in a high sensitivity and reproducibility